Zydus Lifesciences gets approval from USFDA for Bortezomib for Injection

04 May 2022 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial (USRLD: Velcade). Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma. The medication works by slowing or stopping the growth of cancer cells.

The drug will be manufactured at Zydus Hospira. Velcade has a market size of $ 1,172mn (as per IQVIA MAT Mar’22). The group now has 331 approvals and has so far filed over 400 ANDAs since the commencement of filing process in FY 2003-04.

Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

896.55 3.10 (0.35%)
28-Jan-2026 15:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1608.80
Dr. Reddys Lab 1221.00
Cipla 1329.20
Zydus Lifesciences 896.55
Lupin 2125.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×